PHARMAPENDIUM™ Launches Pharmacokinetics Module
Provides unprecedented access to detailed drug pharmacokinetics data and over 1,000,000 extracted exposure observations from the FDA and EMEA documents on more than 2,100 drugs
New York, NY, 14 September, 2010 – Elsevier today announces that it has significantly increased its service offering to pharmaceutical R&D professionals with the launch of a new Pharmacokinetics Module of PharmaPendium™, the online resource for authoritative drug development data. The Pharmacokinetics Module allows pharmacokineticists (and related professionals in regulatory affairs, preclinical, safety pharmacology, etc.) to access multiple exposure parameter measurements under various experimental conditions for over 2,100 drugs, enabling the retrieval and analysis of over 1,000,000 pharmacokinetic observations.
“The new Pharmacokinetics Module is not only a faster and more efficient way to search pharmacokinetics data, it is the only place to find this level of comparative exposure information, great for modeling and comparing therapeutic windows earlier in the development process”, said Philip MacLaughlin, Senior Product Manager at Elsevier. “This is a level of information that stands alone as a resource for Pharmacokinetics data, as it can save months of work.”
With the Pharmacokinetics Module, R&D professionals can model therapeutic windows faster and more accurately than previously possible and discover which preclinical experimental data is predictive of human response, which is not, and why. Users will have the ability to filter comparative data sets for decision support according to a wide variety of fields and special designations, including drug name, species, disease state, food effects, concomitant drugs, route, and exposure parameter.
The PharmaPendium™ module is available exclusively to existing PharmaPendium™customers. Purchase options include annual subscription or data purchase (with annual maintenance fee).
# # #
PharmaPendium™, allows the user to make informed drug development decisions. It is a unique online resource that provides access via a single point to searchable and trusted drug information. It covers close to 4,000 approved drugs, with integrated preclinical, clinical and post-market safety data.
PharmaPendium™ is designed to meet the needs of preclinical safety assessment teams, toxicologists, pharmacokineticists, safety pharmacologists, regulatory affairs staff, pharmacoepidemiologists, clinical researchers, drug discovery informatics and information specialists. It enables text-search of FDA Approval Packages and European Medicines Agency (EMEA) European Public Assessment Reports (EPAR) Approval Documents as well as other data sources. Adverse events and toxicity data are carefully extracted from preclinical and clinical studies from all of these sources. Elsevier offers a broad spectrum of solutions to make processes in drug discovery, preclinical and clinical drug development more efficient, e.g. Reaxys (www.info.reaxys.com), Embase (www.info.embase.com) and PharmaPendium™ (www.info.pharmapendium.com). PharmaPendium™ is owned and protected by Elsevier Properties SA and used under license
About Elsevier Properties SA
Elsevier Properties SA is a center of excellence within Reed Elsevier for the management of intellectual property. Elsevier Properties SA owns the PharmaPendium™, Beilstein and Reaxys databases. Trademarks including Reaxys®, PharmaPendium™ and The Lancet® are owned and protected by Elsevier Properties SA and used under license. For additional information see www.reedelsevier.com.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 33,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact
VP, Global Corporate Relations